TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.81−0.10 (-5.24%)
Close on Nov 18, 2026Market cap $20.95MP/E –Yield –
TherapeuticsMD net income
Net income is the profit left for shareholders after every expense, interest and tax.
TherapeuticsMD's net income for the twelve months ending Jun 30, 2026 was -$217.00K. For fiscal 2025 it was -$569.00K. The highest annual figure on record is $112.00M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$569.00K | – |
| FY2024 | Dec 31, 2024 | -$2.18M | – |
| FY2023 | Dec 31, 2023 | -$10.28M | -109.2% |
| FY2022 | Dec 31, 2022 | $112.00M | – |
| FY2021 | Dec 31, 2021 | -$172.42M | – |
| FY2020 | Dec 31, 2020 | -$183.52M | – |
| FY2019 | Dec 31, 2019 | -$176.15M | – |
| FY2018 | Dec 31, 2018 | -$132.62M | – |
| FY2017 | Dec 31, 2017 | -$76.93M | – |
| FY2016 | Dec 31, 2016 | -$89.88M | – |
| FY2015 | Dec 31, 2015 | -$85.08M | – |
| FY2014 | Dec 31, 2014 | -$54.22M | – |
| FY2013 | Dec 31, 2013 | -$28.42M | – |
| FY2012 | Dec 31, 2012 | -$35.12M | – |
| FY2011 | Dec 31, 2011 | -$12.91M | – |
| FY2010 | Dec 31, 2010 | -$2.87M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $155.00K | -71.9% |
| Q1 FY2026 | Mar 31, 2026 | $95.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$619.00K | -345.6% |
| Q3 FY2025 | Sep 30, 2025 | $152.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $551.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$653.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $252.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$609.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$734.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$883.00K | -101.1% |
| Q3 FY2023 | Sep 30, 2023 | -$3.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.41M | -102.1% |
| Q1 FY2023 | Mar 31, 2023 | -$3.60M | – |
| Q4 FY2022 | Dec 31, 2022 | $77.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.97M | – |
| Q2 FY2022 | Jun 30, 2022 | $112.28M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$42.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$47.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$42.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$39.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$42.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$32.61M | – |
| Q2 FY2020 | Jun 30, 2020 | -$51.98M | – |
| Q1 FY2020 | Mar 31, 2020 | -$56.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$49.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.97M | – |
| Q2 FY2019 | Jun 30, 2019 | -$55.24M | – |
| Q1 FY2019 | Mar 31, 2019 | -$39.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$39.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.61M | – |
| Q2 FY2018 | Jun 30, 2018 | -$33.22M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.67M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.16M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.84M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.02M | – |
See a number that looks wrong?